Arrowhead Pharmaceuticals 경영진
경영진 기준 점검 4/4
Arrowhead Pharmaceuticals CEO는 Chris Anzalone, Dec2007 에 임명되었습니다 의 임기는 18.75 년입니다. 총 연간 보상은 $9.03M, 10.9% 급여 및 89.1% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $313.89M 가치에 해당하는 회사 주식의 2.69% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 3.4 년과 14.8 년입니다.
핵심 정보
Chris Anzalone
최고경영자
US$9.0m
총 보수
| CEO 급여 비율 | 10.86% |
| CEO 재임 기간 | 18.8yrs |
| CEO 지분 보유율 | 2.7% |
| 경영진 평균 재임 기간 | 3.4yrs |
| 이사회 평균 재임 기간 | 14.8yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Sep 03
ARWR: Phase 3 SHASTA Results And Voucher Plan Will Drive Repricing
Analysts have lifted Arrowhead Pharmaceuticals' fair value estimate from $85.00 to $100.00. They cite stronger conviction around plozasiran in severe hypertriglyceridemia, the Madrigal partnership, and recent Phase 3 SHASTA-3 and SHASTA-4 data that underpin higher projected profit margins despite slightly softer revenue growth assumptions and a higher future P/E.
내러티브 업데이트 • Aug 19
ARWR: SHTG Phase 3 Success And PRV Use Will Drive Future Upside
Arrowhead Pharmaceuticals' updated analyst price target has moved from about $89 to about $110. Analysts point to stronger assumptions around plozasiran in severe hypertriglyceridemia, the Madrigal partnership and the planned $215m priority review voucher purchase as key drivers of the revised valuation inputs.
내러티브 업데이트 • Aug 05
ARWR: Cardiometabolic RNAi Readouts In Severe Hypertriglyceridemia Will Drive Future Repricing
Arrowhead Pharmaceuticals' updated analyst price target of $126, up from $110, reflects analysts' higher modeled revenue growth and confidence in plozasiran following positive SHASTA-3 and SHASTA-4 Phase 3 data. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals shows a cluster of higher price targets and supportive commentary tied directly to the Phase 3 SHASTA-3 and SHASTA-4 results for plozasiran in severe hypertriglyceridemia.Seeking Alpha • Jul 22
Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials
Summary Arrowhead Pharmaceuticals reported positive phase 3 results for Redemplo, achieving 79-81% triglyceride reductions and significant acute pancreatitis risk reduction in severe hypertriglyceridemia. Redemplo demonstrates strong efficacy, quarterly dosing, and a favorable safety profile versus Ionis’ Tryngolza, positioning ARWR for leadership in the SHTG market. Tryngolza has a first-mover advantage and administration with an autoinjector versus the current prefilled syringe for Redemplo, but ARWR expects to have an autoinjector as well. I expect modest near-term sales from the small FCS market, with significant revenue potential upon SHTG launch following sNDA submission and likely approval by late 2027. Read the full article on Seeking Alpha내러티브 업데이트 • Jul 21
ARWR: Upcoming SHASTA-3 And 4 Results Will Drive Bullish Repricing
Arrowhead Pharmaceuticals' updated fair value estimate has been lifted from $57.11 to $85.00 as analysts factor in higher Street price targets in the $95 to $98 range, supported by growing optimism around upcoming SHASTA-3/4 data for plozasiran and its potential in severe hypertriglyceridemia. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals centers on the upcoming SHASTA-3/4 data readout for plozasiran in severe hypertriglyceridemia, with several firms updating price targets as they reassess the company’s risk and opportunity profile.내러티브 업데이트 • Jul 07
ARWR: Cardiometabolic Progress And EU Approval Will Support But Not Eliminate SHTG Uncertainty
Arrowhead Pharmaceuticals' analyst price targets have moved higher into the mid $40s, with analysts pointing to updated assumptions on fair value, profitability and revenue trends as key reasons for the reset. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals points to a cluster of price target increases and rating changes that frame how analysts are thinking about valuation, execution risk, and growth potential at current levels in the mid $40s.내러티브 업데이트 • Jun 23
ARWR: Mixed Wave Data And Execution Risks Will Challenge Recent Rebound
Analysts have lifted their price expectations for Arrowhead Pharmaceuticals. The updated fair value estimate has moved from $42.57 to $57.11 as they factor in a slower anticipated revenue decline, a higher projected profit margin, and a slightly lower future P/E multiple.분석 기사 • Jun 20
Arrowhead Pharmaceuticals (ARWR) Stock Could Be 25.6% Undervalued After R And D Webinar Update
Arrowhead Pharmaceuticals (ARWR) recently outlined a Summer Series of R&D webinars focused on its cardiometabolic pipeline, alongside positive clinical updates and upcoming regulatory milestones that have drawn fresh attention to the stock. See our latest analysis for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals’ recent R&D webinar announcement and positive late May clinical readouts have coincided with strong momentum, including a 45.25% 3 month share price return and a very large 1...내러티브 업데이트 • Jun 08
ARWR: Cardiometabolic RNAi Readouts And Licensing Will Drive Future Repricing
Arrowhead Pharmaceuticals' updated analyst price target moves to $46, up from $35, as analysts factor in modestly higher long term growth and margin assumptions, along with a slightly lower discount rate, while keeping fair value unchanged at $110. Analyst Commentary Recent Street research around Arrowhead points to a constructive shift in tone, with a series of bullish analysts highlighting upside drivers tied to execution on the pipeline and the broader biotech backdrop.내러티브 업데이트 • May 25
ARWR: Cardiometabolic RNAi Data And Licensing Will Drive Future Repricing
Analysts have raised Arrowhead Pharmaceuticals' average price target by $11 to $46, citing a stronger sector backdrop, healthier biotech funding conditions, and reassessed growth and profitability assumptions. These are reflected in higher revenue growth expectations and a slightly higher future P/E multiple.내러티브 업데이트 • May 07
ARWR: Cardiometabolic RNAi Data And Licensing Progress Will Drive Future Repricing
Analysts have raised their Arrowhead Pharmaceuticals price target by $12 to $110, citing updated assumptions for a less severe revenue contraction, higher projected profit margins, and a lower forward P/E estimate in recent research. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals has reflected a mix of caution and renewed optimism, with several bullish analysts focusing on price target changes, upgrades, and the implications for valuation and execution risk.내러티브 업데이트 • Apr 21
ARWR: Wave Data Concerns Will Test Sustainability Of Recent Share Price Rebound
Arrowhead Pharmaceuticals' analyst price target has edged higher by about $0.26 to $42.57, with analysts pointing to updated views on profit margins and P/E assumptions following a mix of recent target raises and trims across the Street. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals reflects a split view, with some firms lifting targets sharply and others trimming expectations.내러티브 업데이트 • Apr 06
ARWR: RNAi Obesity And Cardiometabolic Data Will Drive Future Repricing
Narrative update on Arrowhead Pharmaceuticals The consensus analyst price target for Arrowhead Pharmaceuticals has been adjusted to $110. This reflects mixed recent research that pairs questions around Wave Life Sciences data with higher targets from several firms citing early obesity program results and the Redemplo launch.내러티브 업데이트 • Mar 23
ARWR: Obesity RNAi Data And Cardiometabolic Franchise Will Drive Future Repricing
Analysts have updated their views on Arrowhead Pharmaceuticals with a revised blended price target of $110. This reflects mixed shifts in assumptions around discount rate, revenue growth, profit margins and future P/E after recent obesity and cardiometabolic data, as well as the Redemplo launch.내러티브 업데이트 • Mar 09
ARWR: Obesity RNAi Data Will Test Sustainability Of Recent Share Price Rebound
Analysts have reduced their blended price target on Arrowhead Pharmaceuticals by about $2 to reflect a lower fair value estimate of $42.31. This incorporates more cautious assumptions on near term revenue growth and margins, even as recent research notes highlight supportive early obesity data and emerging cardiometabolic opportunities.내러티브 업데이트 • Feb 22
ARWR: Obesity And Cardiometabolic Pipeline Progress Will Drive Future Repricing
Narrative Update: Arrowhead Pharmaceuticals The updated analyst price framework for Arrowhead Pharmaceuticals keeps fair value at $110 while trimming implied future P/E assumptions, reflecting analysts' mixed but generally constructive reaction to recent obesity and cardiometabolic data and the Redemplo launch. Analyst Commentary Recent research updates on Arrowhead Pharmaceuticals cluster around two themes you should keep in mind: confidence in the obesity and cardiometabolic pipeline, and growing interest in the early commercial rollout of Redemplo.분석 기사 • Feb 12
Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality
Arrowhead Pharmaceuticals, Inc.'s ( NASDAQ:ARWR ) earnings announcement last week was disappointing for investors...내러티브 업데이트 • Feb 08
ARWR: Obesity Pipeline Progress Will Drive Future Repricing In My View
Analysts raised their fair value estimate for Arrowhead Pharmaceuticals to $110 from $80 as they incorporate updated assumptions on Redemplo's launch, initial obesity pipeline data, and a lower projected future P/E multiple, while also reflecting slightly higher risk and more conservative expectations for revenue growth. Analyst Commentary Bullish analysts are leaning into Arrowhead's transition from a pure development story toward one with its first approved product and an emerging obesity pipeline, and they are adjusting their models to reflect both assets.내러티브 업데이트 • Jan 25
ARWR: Early Obesity RNAi Data Will Challenge Durability Of Recent Share Repricing
Narrative update on Arrowhead Pharmaceuticals The updated analyst price target for Arrowhead Pharmaceuticals shifts to reflect a fair value of $44.02. Analysts point to Redemplo's approval and launch, early data from the ARO INHBE and ARO ALK7 obesity programs, and increased confidence in the pipeline as key factors in their revised outlook.내러티브 업데이트 • Jan 11
ARWR: Obesity RNAi Data Will Test Sustainability Of Recent Share Repricing
Arrowhead Pharmaceuticals' analyst fair value estimate moved from $17.00 to about $44.94, as analysts cited early obesity trial data for ARO INHBE and ARO ALK7, validation of the TRiM RNAi platform, and the first FDA approval of Redemplo as key reasons for higher price targets in the US$80 range. Analyst Commentary Street research around Arrowhead has tilted more constructive around the obesity franchise, with multiple firms lifting their fair value estimates into the US$80 range after the initial ARO INHBE and ARO ALK7 data.내러티브 업데이트 • Dec 18
ARWR: Upcoming SHTG Readouts Will Temper Optimism Despite Recent Cardiometabolic Progress
Analysts have raised their price targets on Arrowhead Pharmaceuticals by roughly $6 to the mid $40s to low $60s range, citing the FDA approval of Redemplo, a strengthened commercial outlook in familial chylomicronemia syndrome and sHTG, and underappreciated long term cost and margin advantages. Analyst Commentary Bullish analysts view Redemplo's FCS approval as a key de-risking event that supports higher valuation multiples and justifies recent price target increases into the high $40s to low $60s range.내러티브 업데이트 • Dec 04
ARWR: Upcoming SHTG Data Will Likely Undermine Optimistic Cardiometabolic Expectations
Analysts have nudged their average price target on Arrowhead Pharmaceuticals higher to about $58 from $55, citing the FDA approval of Redemplo, expectations for a broader sHTG label, and underappreciated long term cost and margin advantages. Analyst Commentary Research coverage following the Redemplo approval has generally tilted positive, with several firms lifting their price targets and highlighting both the commercial opportunity in sHTG and Arrowhead's long term margin profile.분석 기사 • Dec 02
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry
Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shares have continued their recent momentum with a 33% gain in the last...내러티브 업데이트 • Nov 20
ARWR: FDA Milestone Will Drive Cost Advantage In Cardiometabolic Markets
Analysts have raised Arrowhead Pharmaceuticals' fair value estimate from $47.50 to $55.00 per share after the FDA approved Redemplo and expressed increased confidence in the company's commercial execution and cost advantages. Analyst Commentary Following the recent FDA approval of Redemplo, analysts have provided updated perspectives on Arrowhead Pharmaceuticals' valuation and prospects.내러티브 업데이트 • Nov 06
ARWR: Expect Cost Efficiency To Drive Competitive Advantage In Upcoming Metabolic Trials
Analysts have significantly raised their price target for Arrowhead Pharmaceuticals, increasing it from $38 to $61 per share. They cite structural cost advantages and an underappreciated long-term gross margin potential as key factors for this change.내러티브 업데이트 • Oct 22
Analysts Boost Arrowhead Pharmaceuticals Price Target Amid Cost Advantages and Strategic Partnerships
Arrowhead Pharmaceuticals' analyst price target has been raised from $45 to $47.50 per share. Analysts highlight the company's structural cost advantages and improved margin outlook.분석 기사 • Oct 07
What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You
Despite an already strong run, Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shares have been powering on, with a...내러티브 업데이트 • Oct 05
RNAi Pipeline Will Unlock Emerging Markets Despite Regulatory Risks
Analysts have slightly lowered their price target for Arrowhead Pharmaceuticals from $46.15 to $45.00, citing ongoing concerns following recent strategic divestitures by partners and modest shifts in the company's projected financials. Analyst Commentary Recent analyst research provides a mixed outlook for Arrowhead Pharmaceuticals following notable events involving partner Sarepta Therapeutics.내러티브 업데이트 • Sep 08
RNAi Pipeline Will Unlock Emerging Markets Despite Regulatory Risks
The consensus price target for Arrowhead Pharmaceuticals has increased modestly as its Future P/E has risen and Net Profit Margin has declined, resulting in a new analyst fair value of $46.15. What's in the News Arrowhead Pharmaceuticals announced a major global licensing and collaboration agreement with Novartis for ARO-SNCA, its preclinical siRNA therapy for synucleinopathies such as Parkinson’s Disease; the deal includes a $200 million upfront payment to Arrowhead, potential milestones up to $2 billion, and future royalties, with closing expected in the second half of 2025 (Key Developments).CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$320m |
| Mar 31 2026 | n/a | n/a | -US$301m |
| Dec 31 2025 | n/a | n/a | US$202m |
| Sep 30 2025 | US$9m | US$981k | -US$2m |
| Jun 30 2025 | n/a | n/a | -US$148m |
| Mar 31 2025 | n/a | n/a | -US$144m |
| Dec 31 2024 | n/a | n/a | -US$640m |
| Sep 30 2024 | US$12m | US$951k | -US$599m |
| Jun 30 2024 | n/a | n/a | -US$539m |
| Mar 31 2024 | n/a | n/a | -US$471m |
| Dec 31 2023 | n/a | n/a | -US$297m |
| Sep 30 2023 | US$10m | US$903k | -US$205m |
| Jun 30 2023 | n/a | n/a | -US$181m |
| Mar 31 2023 | n/a | n/a | -US$150m |
| Dec 31 2022 | n/a | n/a | -US$155m |
| Sep 30 2022 | US$12m | US$863k | -US$176m |
| Jun 30 2022 | n/a | n/a | -US$154m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | n/a | n/a | -US$183m |
| Sep 30 2021 | US$25m | US$837k | -US$141m |
| Jun 30 2021 | n/a | n/a | -US$126m |
| Mar 31 2021 | n/a | n/a | -US$110m |
| Dec 31 2020 | n/a | n/a | -US$103m |
| Sep 30 2020 | US$14m | US$786k | -US$85m |
| Jun 30 2020 | n/a | n/a | -US$24m |
| Mar 31 2020 | n/a | n/a | US$10m |
| Dec 31 2019 | n/a | n/a | US$53m |
| Sep 30 2019 | US$2m | US$674k | US$68m |
보상 대 시장: Chris의 총 보수(USD9.03M)는 US 시장에서 비슷한 규모 기업의 평균(USD14.76M)보다 낮습니다.
보상과 수익: Chris의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Chris Anzalone (57 yo)
18.8yrs
재임 기간
US$9,029,861
보수
Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007 and serves as its Chairman. He serves a...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Chairman | 18.8yrs | US$9.03m | 2.69% $ 313.9m | |
| Chief Financial Officer | 1.3yrs | US$2.33m | 0.0091% $ 1.1m | |
| COO & Secretary | 4.2yrs | US$3.03m | 0.24% $ 28.0m | |
| Chief Medical Officer and Head of R&D | no data | US$2.97m | 0.16% $ 18.8m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | 데이터 없음 | 데이터 없음 | |
| Chief Scientific Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Head of Investor Relations & VP | no data | 데이터 없음 | 데이터 없음 | |
| Director of Communications | 21.1yrs | 데이터 없음 | 데이터 없음 | |
| Chief Medical Scientist | 2.6yrs | US$16.34m | 데이터 없음 | |
| Head of Toxicology & VP | no data | 데이터 없음 | 데이터 없음 | |
| Head of Tax | 4.7yrs | 데이터 없음 | 데이터 없음 | |
| SVP of Cardiovascular & Head of Metabolic Franchise | 1.8yrs | 데이터 없음 | 데이터 없음 |
3.4yrs
평균 재임 기간
61yo
평균 나이
경험이 풍부한 관리: ARWR의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3.4 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Chairman | 18.8yrs | US$9.03m | 2.69% $ 313.9m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 14.8yrs | US$428.18k | 0.073% $ 8.6m | |
| Independent Lead Director | 8.7yrs | US$438.18k | 0.035% $ 4.0m | |
| Member of Hepatitis B Clinical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Chairman of Hepatitis B Clinical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 16.1yrs | US$420.68k | 0.043% $ 5.1m | |
| Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Hepatitis B Clinical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Hepatitis B Clinical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Hepatitis B Clinical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 4.3yrs | US$424.43k | 0.020% $ 2.3m |
14.8yrs
평균 재임 기간
67yo
평균 나이
경험이 풍부한 이사회: ARWR의 이사회는 노련하고 경험이 풍부합니다(평균 재임 14.8 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/11 02:52 |
| 종가 | 2026/09/11 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/09/30 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Arrowhead Pharmaceuticals, Inc.는 28명의 분석가가 다루고 있습니다. 이 중 14명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Ying Huang | Barclays |
| Jason Matthew Gerberry | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |